Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Insmed Incorporated
A new batch of marketing authorizations in Japan includes new therapies for high-need cancer indications and rare diseases, and the first nod worldwide for a novel lysosomal disorder treatment that can address serious CNS symptoms.
IPO Edition: Sana leads the group with a $587.5m initial public offering, while Immunocore and Bolt follow with $200m-plus IPOs. The 10 newly public companies generated a 43.3% average return on 8 Feb.
Last year saw the number of applications accepted onto the European Medicines Agency’s priority medicines scheme inch up and the notoriously high rejection rate for applications drop.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
- Controlled Release
- Site Specific
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Insmed, Inc.
- Transave Inc.